A decade of improvement in Chronic Lymphocytic... - CLL Support
A decade of improvement in Chronic Lymphocytic Leukemia treatments means a shorter life expectancy is no longer a given
You need to be a member of this community to see this post.
Read more about...
12 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
10 Years in CLL: Top Advances From 2012-2022
For some of you, this is the story you witnessed.
For some of us, this is the near or more distant...
Advances in Targeted Therapy for R/R CLL OncLive videos & transcripts by Nirav Shah MD & Nicole Lamanna MD
Advances in Targeted Therapy for R/R CLL
(These OncLive presentations are intended for medical...
BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'
In just a short time, in many places, BTK inhibitors (BTKi) have largely replaced...
Median PFS for FCR treated CLL patients with IGHV-M was 14.6 years vs 4.2 years for patients with IGHV-UM. V+O and I+R look to be superior
An update of the long-term follow-up results from the original 300-patient FCR (fludarabine,...
Managing the cardiovascular risk of Bruton's Tyrosine Kinase Inhibitors in chronic lymphocytic leukemia
The American Society of Hematology journal Blood Advances published an important...
Related Posts
- YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success
BTK Degrader Shows Potential for Treating Refractory CLL and SLL- Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
- Zanubrutinib vs. Ibrutinib Patient Power Video by Dr. Jennifer Brown MD PHD
- Chronic lymphocytic leukemia treatment algorithm 2022
